Immune status of patients with multiple sclerosis. Analysis of primary and established immune responses in 24 patients.
D000328:Adult; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects*; D000942:Antigens, Bacterial; D002986:Clinical Trials as Topic; D003168:Complement Fixation Tests; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular / Q000187:drug effects*; D007114:Immunization; D007136:Immunoglobulins / Q000032:analysis; D007252:Influenza Vaccines; D008213:Lymphocyte Activation; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology*; D010919:Placebos; D012882:Skin Tests
D000906:Antibodies; D000942:Antigens, Bacterial; D007136:Immunoglobulins; D007252:Influenza Vaccines; D010919:Placebos; D015122:Mercaptopurine; D008727:Methotrexate